69
~~44~~

We CLAIM:

1. A kallikrein inhibiting protein which comprises a non-naturally occurring Kunitz domain, wherein, at each of the residues of said domain corresponding to the below identified residues of BPTI, one of the following allowed amino acids is found:

BPTI residue #	Allowed Amino Acid
10	Asp, Glu, Ala, Gly, Ser, Thr
11	Asp, Gly, Ser, Val, Glu, Leu, Met, Asn, Ile, Ala, Thr
12	Gly, and, if residue 14 or 38 is not Cys, any conservative or semi-conservative substitution for a "normal" conformation Gly as defined in Table 9
13	Arg, His, Pro, Asn, Ser, Thr, Ala, Gly, Lys, Gln
14	Cys, and, if residue 38 is not Cys, any conservative or semi-conservative substitution for Cys
15	Arg, Lys, Ala, Ser, Gly, Met, Asn, Gln
16	Ala, Gly, Ser, Asp, Asn
17	Ala, Asn, Ser, Ile, Gly, Val, Gln, Thr
18	His, Leu, Gln, Ala
19	Pro, Gln, Leu, Asn, Ile
20	Arg, Leu, Ala, Ser, Lys, Gln, Val

T0830X

83

70
45

21	Trp, Phe, Tyr, His, Ile
31	Glu, Asp, Gln, Asn, Ser, Ala, Val, Leu, Ile, Thr
32	Glu, Gln, Asp, Asn, Pro, Thr, Leu, Ser, Ala, Gly, Val
33	Phe, Tyr
34	Ser, Thr, Ile, Val, Ala, Asn, Gly, Leu
35	Tyr, Trp, Phe
36	Gly, Ser, Ala
37	Gly, and, if residue 14 or 38 is not Cys, any conservative or semi-conservative substitution for a "normal" conformation Gly as defined in Table 9
38	Cys, and, if residue 14 is not Cys, any conservative or semi-conservative substitution for Cys
39	Gly, Glu, Ala, Ser, Asp.

5

2. A kallikrein inhibiting protein which comprises a non-naturally occurring Kunitz domain, wherein, at each of the residues corresponding to the below identified residues, one of the following allowed amino acids is found:

T0840X

BPTI residue #	Allowed Amino Acid
10	Asp, Glu, Ala, Gly, Ser, Thr
11	Asp, Gly, Ser, Val, Glu, Leu, Met
12	Gly, and, if residue 14 or 38 is not Cys, or any conservative

84

71
46

	semi-conservative substitution for a "normal" conformation Gly as defined in Table 9
13	Arg, His, Pro, Asn, Ser
14	Cys, and, if residue 38 is not Cys, any conservative or semi-conservative substitution for Cys
15	Arg, Lys
16	Ala, Gly
17	Ala, Asn, Ser, Ile
18	His, Leu, Gln
19	Pro, Gln, Leu
20	Arg, Leu, Ala, Ser, Lys, Gln, Val
21	Trp, Phe
31	Glu
32	Glu, Gln
33	Phe
34	Ser, Thr, Ile
35	Tyr
36	Gly, Ser, Ala
37	Gly, and, if residue 14 or 38 not Cys, any conservative or semi-conservative substitution for a "normal" conformation Gly as defined in Table 9
38	Cys, and, if residue corresponding to position 14 is not Cys, any conservative or semi-conservative substitution for Cys

95

72

39	Gly, Glu, Ala.

3. The protein of claim 2 wherein, the Kunitz domain is further characterized as follows:

BPTI Residue No.	Allowed Residue
10	Asp, Glu
11	Asp, Gly, Ser, Val
12	Gly
14	Cys
20	Arg
36	Gly
37	Gly
38	Cys.

4. A plasma kallikrein inhibiting protein which comprises a sequence that is substantially homologuous to a reference sequence selected from the group consisting of KKII/3 #1, KKII/3 #2, KKII/3 #3, KKII/3 #4, KKII/3 #5, KKII/3 #6, KKII/3 #7, KKII/3 #8, KKII/4 #9, KKII/3 #10, KK2/#11, KK2/#13, KK2/#1, KK2/#2, KK2/#3, KK2/#4, KK2/#6, KK2/#7, KK2/#8, KK2/#9, KK2/#10, KK2/#12, AND KK2con1 as defined in Table 2.

5. A method of ~~preventing or~~ treating a disorder attributable to excessive kallikrein activity which comprises administering, to a human or animal subject who would benefit therefrom, a kallikrein-inhibitory amount of the protein of claim 1 ~~any of claims 1-4~~.

6. A method of assaying for kallikrein which comprises providing

73
~~48~~

A the protein of ~~any of claims 1-4~~ claim 1 in labeled or insolubilized form, and determining whether a complex of said protein and the kallikrein in a sample is formed.

Sub B4 Cont. A

7. A method of purifying kallikrein from a mixture which comprises providing the protein of ~~any of claims 1-4~~ claim 1 in insolubilized form, and contacting the mixture with said insolubilized protein or analogue so that kallikrein in the mixture is bound.

Add A1

Add B2